skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Collaborations are commonplace in HIV treatment trials and leverage expertise and experience of individual parties as researchers work toward ending this ongoing epidemic, but does study implementation slow down when too many parties are involved? In particular, is there any impact on recruitment rates when various sponsor types collaborate?

Highlights in this white paper include:

This analysis takes a closer look at Phase II-III studies in HIV-positive patients in order to determine whether collaboration has any effect on enrollment trends in clinical trials evaluating antiretroviral treatment.


  • Average site and trial enrollment rates for single sponsor vs.
    collaborative studies by sponsor type
  • The effect of collaboration and number of sponsors on trial performance levels
  • How site enrollment rates and number of sites differ for four sponsor types,
    including industry, collaborative group, government agency and hospital/academic/medical center
  • The effect of trial size on enrollment trends and more


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: